Search Results

AmpliPhi Biosciences Corporation and C3J Therapeutics, Inc. (“C3J”), a private clinical stage biotechnology company focused on the development of novel targeted antimicrobials, today announced that the companies have entered into a definitive agreement under which a wholly owned subsidiary of AmpliPhi will merge with C3J

C3J’s pending merger with AmpliPhi Biosciences, which will create a clinical-stage phage leader, is on track to close in May 2019

Armata Pharmaceuticals, Inc announced that the previously-announced merger between C3J Therapeutics, Inc.

C3J Therapeutics and Synthetic Genomics, Inc., (SGI) a leader in designing and programming biology for desired function, announced an agreement between the two companies to integrate SGI’s proprietary engineered bacteriophage (or phage) platform with C3J’s R&D programs addressing high unmet medical needs linked to infectious diseases.

Approximately 94% of the shares voted at the special stockholder meeting voted in favor of the transaction, with each of the other related proposals also receiving sufficient votes for approval.

Entered into a merger agreement with C3J Therapeutics that is expected to result in an NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating the Board of Directors of AmpliPhi Biosciences Corporation related to the sale of the Company to C3J Therapeutics, Inc.